Skip to main content

Synergistic effects of TGIF and interferonγ (IFN-γ) on tumor cell growthTGIF and IFN-γ

Biotherapy volume 2, pages 33–40 (1990)Cite this article

Abstract

Interferon-γ (IFN-γ) and tumor growth inhibitory factor (TGIF) were inducedin vitro in the supernatant from mixed culture of human peripheral blood mononuclear cells (PBMC) and OK-432. TGIF activity was determined by growth inhibition of a human gastric adenocarcinoma cell line, MK-1 cells, and IFN-γ activity was measured by radioimmunoassay. The production of TGIF and IFN-γ was time-dependent, reaching its maximum around 48 hrs. Although there was no significant correlation between TGIF production and IFN-γ production, combination of a subthreshold concentration of recombinant IFN-γ (rIFN-γ) and TGIF induced significant growth inhibition of MK-1 cells. This fact indicates that the effects of rIFN-γ and TGIF are synergistic. The antiproliferative effect of these cytokines are highly species-specific, and their synergistic effects were also species-specific. rIFN-γ-sensitive and -resistant clones were successfully established from the original MK-1 cell line; those clones are both sensitive to TGIF. Synergistic antiproliferative effects were found when the rIFN-γ-sensitive clone, but not the resistant clone, was used as a target, suggesting that the synergistic effects require the target cells' sensitivity to IFN-γ. These results indicate that the synergistic effects of TGIF and IFN-γ may produce a clinical antitumor action in cancer patients receiving OK-432 administration.

This is a preview of subscription content, access via your institution.

References

  1. Gresser I. How dose interferon inhibit tumor growth In: Gresser I, ed. Interferon 6. New York: Academic Press, 1985, 1–12.

    Google Scholar 

  2. Denz H, Lechleitner M, Marth C, Daxenbichler G, Gastle G, Braunsteiner H. Effect of human recombinantα-2 andγ-interferon on the growth of human cell lines from solid tumors and hematologic malignancies. J Interferon Res 1985; 5: 147–57.

    PubMed  Google Scholar 

  3. Aiyer AR, Serrano LE, Jones PP. Interferon-γ binds to high and low affinity receptor components on murine macrophages. J Immunol 1986; 136: 3329–34.

    PubMed  Google Scholar 

  4. O'Connell MJ, Moertel CG, Schutt AJ, Sherwin SA. Phase II clinical trial of human recombinantγ interferon in patients with advanced colorectal cancer. Proc Am Assoc Cancer Res 1986; 27: 181.

    Google Scholar 

  5. Ernstoff MS, Trautman T, Davis CA. A randomized Phase I/II study of continuous versus intermittent intravenous interferonγ in patients with metastatic melanoma. J Clin Oncol 1987; 5: 1804–10.

    PubMed  Google Scholar 

  6. Oleszak E, Stewart WE. Potentiation of the antiviral and anticellular activities of interferons by mixtures of HUIFN-γ and HUIFN-α or HUIFN-β. J Interferon Res 1985; 5: 361–71.

    PubMed  Google Scholar 

  7. Balkwill FR, Ward BG, Moodie E, Fiers W. Therapeutic potential of tumor necrosis factor-α andγ-interferon in experimental human ovarian cancer. Cancer Res 1987; 47: 4755–8.

    PubMed  Google Scholar 

  8. McIntosh JK, Mule JJ, Merino MJ, Rosenberg SA. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-α. Cancer Res 1988; 48: 4011–7.

    PubMed  Google Scholar 

  9. Watanabe Y, Iwa T. Clinical value of immunotherapy for lung cancer by the streptococcal preparation, OK-432. Cancer 1984; 53: 248–53.

    PubMed  Google Scholar 

  10. Kikkawa N, Kawahara T. A study on adjuvant immunochemotherapy for colorectal cancer. In: Ota K, ed: Clinical application of OK-432 for control of cancer. Tokyo: Excerpta Medica, 1986; 26–37.

    Google Scholar 

  11. De Ley M, Claeys H. Streptococcal preparation OK-432-induced interferon in human leukocytes: purification and characterization. Int Archs Allergy appl Immun 1984; 74: 21–8.

    Google Scholar 

  12. Ichimura O, Suzuki S, Saito M, Sugawara Y, Ishida N. Augumentation of interleukin 1 and interleukin 2 production by OK-432. Int J Immunopharmacol 1985; 7: 263–70.

    PubMed  Google Scholar 

  13. Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitsu Y, Urushizaki I. Release of tumor necrosis factor (TNF) into mouse peritoneal fluid by OK-432, a streptococcal preparation. Immunopharmacology 1986; 11: 79–86.

    PubMed  Google Scholar 

  14. Katano M, Yamamoto H, Mizoguchi T, Hisatsugu T. Induction of tumor growth inhibitory factor (TGIF) in human mononuclear cells by OK-432, a streptococcal preparation. Cancer Immunol Immunother 1988; 27: 198–204.

    PubMed  Google Scholar 

  15. Katano M, Yamamoto H, Mizoguchi T, Iyama A, Matsuo T, Nakamura M, Hisatsugu T, Torisu M. Induction of a tumor growth inhibitory factor (TGIF) in human mononuclear cells by OK-432. Possible clinical use of TGIF. In: Torisu M, Yoshida T, eds. International symposium on new horizons in tumor immunotherapy. Amsterdam: Elsevier, 1989 (In press).

    Google Scholar 

  16. Okamoto H, Shoin S, Minami M, Koshimura S, Shimizu R. Experimental anticancer studies, part XXX. Factors influencing the streptolysin-S-forming ability of streptococcal having anticancer activity. Jpn J Exp Med 1966; 36: 161–74.

    PubMed  Google Scholar 

  17. Tanaka E, Imai M, Usuda S, Tachibana K, Okamoto H, Ohike Y, Nakamura T, Miyakawa Y, Mayumi M. A two-site sandowich radioimmunoassay of human gamma interferon with monoclonal antibodies. J Immunol Methods 1985; 77: 275–82.

    PubMed  Google Scholar 

  18. Committee on Interferon Nomenclature: interferon nomenclature. Nature (London) 1980; 286: 110.

    Google Scholar 

  19. Saito M, Ebina T, Koi M, Yamaguchi T, Kawada Y, Ishida N. Induction of interferon-γ in mouse spleen cells by OK-432 a preparation of streptococcus pyogenes. Cell Immunol 1982; 68: 187–92.

    PubMed  Google Scholar 

  20. Noda T, Asano M, Yoshie O, Suzuki R, Ebina T, Ishida N. Interferon-γ induction in human peripheral blood mononuclear cells by OK-432, a killed preparation of Streptococcus pyogenes. Microbiol Immunol 1986; 30: 81–6.

    PubMed  Google Scholar 

  21. Torisu M, Katano M, Kimura Y, Itoh H, Takesue M: New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 1983; 93: 357–64.

    PubMed  Google Scholar 

  22. Nagao E. Treatment of pleural carcinomatosis with intracavitary OK-432. In: Ota K, ed. Clinical application of OK-432 for control of cancer. Tokyo: Excerpta Medica, 1986; 161–73.

    Google Scholar 

  23. Katano M, Mizoguchi T, Yamamoto H, Hisatsugu T, Torisu M. Management of malignant ascites by intraperitoneal injection of OK-432. Possible mechanism of the reduction of original tumor mass volume. J Jpn Surg Soc 1987; 88: 1676–83 (Summary in English).

    Google Scholar 

Download references

Author information

Affiliations

  1. Department of Surgery, Saga Medical School, 840-01, Nabeshima-cho, Saga, Japan

    Mitsuo Katano, Hiroshi Yamamoto, Mitsunari Nakamura, Tatsuya Matsuo & Takeharu Hisatsugu

Authors
  1. Mitsuo Katano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitsunari Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tatsuya Matsuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takeharu Hisatsugu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Katano, M., Yamamoto, H., Nakamura, M. et al. Synergistic effects of TGIF and interferonγ (IFN-γ) on tumor cell growthTGIF and IFN-γ . Biotherapy 2, 33–40 (1990). https://doi.org/10.1007/BF02172074

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02172074

Key words

  • IFN-γ
  • synergistic effect
  • TGIF